Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
-
Noosa News24 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General23 hours agoFederal Labor makes $100m Canberra convention centre funding pledge for planning, new aquatic centre
-
General18 hours agoTribute unveiled for SA Police Brevet Sergeant Jason Doig after fatal 2023 shooting
-
Noosa News4 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred